Lordick, Florian
Al-Batran, Salah-Eddin
Ganguli, Arijit
Morlock, Robert
Sahin, Ugur
Türeci, Özlem
Funding for this research was provided by:
Universität Leipzig
Article History
Received: 16 September 2020
Accepted: 23 December 2020
First Online: 23 March 2021
Compliance with ethical standards
:
: Florian Lordick reports personal fees and/or grants from Astellas, AstraZeneca, BMS, BioNTech, Lilly, Elsevier, Infomedica, Merck, MSD, Roche, Servier, and Amgen. Salah-Eddin Al-Batran reports advisory role from Merck, Roche, Celgene, Lilly, Nordic Pharma, Bristol-Myers Squibb, MSD Sharp & Dohme; speaker role from Roche, Celgene, Lilly, Nordic Pharma, AIO gGmbH, MCI, Promedicis, Forum für Medizinische Fortbildung; CEO/founder of IKF Klinische Krebsforschung GmbH; and clinical trial fees from Sanofi, Merck, Roche, Celgene, Vifor, Medac, Hospira, Lilly, German Cancer Aid (Krebshilfe), and German Research Foundation; and translational research from the Federal Ministry of Education and Research. Arijit Ganguli is an employee of Astellas Pharma, Inc. Robert Morlock is a former independent consultant with YouCareChoice supporting Astellas Pharma, Inc., and reports personal fees from Astellas Pharma, Inc., Abbot Medical Optics, Ironwood, and Genentech. Ugur Sahin reports co-founder and shareholder at Ganymed and also holds several patents, with royalties paid by Astellas; founder, chief executive officer, and shareholder of BioNTech. Özlem Türeci reports founder and chief executive officer of Ganymed until the end of 2016; currently an employee and chief medical officer of BioNTech; patents for the investigational agent, zolbetuximab, with royalties paid by Astellas; consultancy fees from Astellas Pharma.